Colostrum: Nature's Own Immune Regulator & Psoriasis

I've been reviewing a number of articles & research papers regarding the link between colostrum and psoriasis, and these are the tip of the iceberg. There is much to learn and discover when it comes to this disease! Abnormal infiltration, proliferation and activation of dendritic cells within psoriatic lesions lead to T cell activation and proliferation, which in turn promotes keratinocyte activation and proliferation.

Milk growth factors as health products: Some technological aspects

Yves Pouliot Sylvie F. Gauthier

• Groupe STELA, Institut des Nutraceutiques et Aliments Fonctionnels (INAF), Université Laval, Québec, Canada G1K 7P4

Abstract

Bovine milk and colostrum contain growth factors such as insulin-like growth factor IGF-I, IGF-II, transforming growth factor TGF-β1, TGF-β2, epidermal growth factor EGF, basic fibroblast growth factor bFGF and platelet-derived growth factor PDGF. A number of methodologies for the extraction of milk growth factors from milk, colostrum or whey have been developed. Cation-exchange chromatography has been widely used because of the basic nature of the growth factors. Also, microfiltration has been used for the concentration of some growth factors from colostrum, while ultrafiltration was successful only in separating IGF-I from IGF-II in whey. Growth factor extracts from milk, colostrum or whey have been used as therapeutic preparations for wound healing and in the treatment of inflammatory gut disorders. More recent applications are related to bone tissue regeneration and treatment of inflammatory skin diseases such as psoriasis.

Safety and Efficacy of a Milk-derived Extract in the Treatment of Plaque Psoriasis: An Open-label Study

Y. Poulin, Y. Pouliot, E. Lamiot, N. Aattouri and S.F. Gauthier

Abstract

Background

XP-828L is a nutraceutical compound obtained by the extraction of a growth factors-enriched protein fraction from bovine milk. XP-828L may improve psoriasis.

Objectives

An open-label study was performed to determine the efficacy, tolerability and safety of XP-828L in the treatment of plaque psoriasis.

Methods

Eleven adult patients with chronic, stable plaque psoriasis on 2% or more of body surface area (BSA) received 5g of oral XP-828L twice daily for 56 days.

Results

All 11 patients completed the 56 days of treatment. At day 28, 6 of the 11 patients showed a reduction in PASI score. At 56 days, seven subjects had a decrease in PASI score ranging from 9.5% to 81.3%. Eight (8) out of 11 patients agreed to participate in an additional 8-week extension treatment phase. Improvement of psoriasis was maintained during the extension period. No clinically significant adverse events or laboratory abnormalities occurred.

Conclusion

XP-828L may improve psoriasis in patients with mild-to-moderate psoriasis.